Ensera launches alliance network for drug-device products

Ensera has launched the Ensera Alliance Network, bringing together device platform and fill-finish specialists to address the complexity of commercialising drug-device combination products, according to Med Techinsights.

The network currently includes injector platform providers SHL Medical, Stevanato Group and Ypsomed. Fill-finish specialists Argonaut Manufacturing Services and American Injectables are also included.

Network brings together named specialists

Med Techinsights reported that the Ensera Alliance Network combines organisations involved in injector platforms with organisations identified as fill-finish specialists. The announcement centers on drug-device combination products and the complexity associated with bringing those products to market.

Ensera’s network includes SHL Medical, Stevanato Group and Ypsomed as injector platform providers. Argonaut Manufacturing Services and American Injectables participate as fill-finish specialists, Med Techinsights said.

The alliance is presented as a network for the commercialisation of drug-device combination products. Med Techinsights described the participating companies as device platform and fill-finish specialists.

Companies currently included

• SHL Medical is identified as an injector platform provider.
• Stevanato Group is identified as an injector platform provider.
• Ypsomed is identified as an injector platform provider.
• Argonaut Manufacturing Services is identified as a fill-finish specialist.
• American Injectables is identified as a fill-finish specialist.

Commercialisation is the stated focus

According to Med Techinsights, bringing a combination product to market often requires pharmaceutical participation across multiple specialist areas. Ensera’s announcement groups the named injector platform providers and fill-finish specialists within the Ensera Alliance Network.

For medical and veterinary sales professionals following injectable therapies, drug delivery devices and combination products, the announcement identifies the organisations currently participating in Ensera’s alliance. Med Techinsights characterized the network as an effort to address commercialisation complexity for drug-device combination products.

The report names Ensera, SHL Medical, Stevanato Group, Ypsomed, Argonaut Manufacturing Services and American Injectables as part of the network announcement.